100% Of Pharma Earnings Growth Last Year Came From Price RisesRupert Hargreaves
Drug pricing has been a hot issue for the past few years and was debated multiple times on the campaign trail by both Trump and Hillary. So far, there’s been little action to curb drug price increases, however, with Trump more focused on arguing with the press and other lawmakers occupied with more urgent matters. For the pharma sector, this is good news, although patients are hardly celebrating.
Still, while it may seem . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.